Mr. Paul Kim is the Chief Strategy Officer of Genopis, and CEO/Founder of Medivate Partners. Together with Helixmith (formerly ViroMed), Medivate has created Genopis in 2018 to become an emerging, global biological CMO.
Mr. Kim has over 24 years of professional experience in R&D and business management in the bio industry. He started his career in 1994 at Genentech, a global leader in biotechnology. Before founding Medivate, Mr. Kim led the Novartis Venture Fund investments in Korea as the Head of the Fund, and also served Head of POSCO BioVentures, a $62M venture fund focused on U.S. and EU biotech investments on behalf of POSCO, a $40B steel conglomerate. Mr. Kim also served executive roles at Helixmith and CrystalGenomics. Mr. Kim received his bachelor’s degree in molecular cell biology from UC Berkeley, and is a graduate of the Life Sciences Executive program. In addition to Genopis, Mr. Kim serves on boards of several biotech companies globally.